1887

Abstract

African horsesickness virus serotype 4 (AHSV-4) outer capsid protein VP2, or VP2 and VP5 plus inner capsid protein VP7, derived from single or dual recombinant baculovirus expression vectors were used in different combinations to immunize horses. When the proteins were purified by affinity chromatography, the combination of all three proteins induced low levels of neutralizing antibodies and conferred protection against virulent virus challenge. However, purified VP2 or VP2 and VP5 in the absence of VP7 failed to induce neutralizing antibodies and protection. Immunization with non-purified proteins enhanced the titres of neutralizing antibodies. Again, the combination of the three proteins was able to confer total protection to immunized horses, which showed absence of viraemia. The antigenicity of recombinant VP2 was analysed with a collection of 30 MAbs. Both purified and unpurified recombinant VP2 proteins showed different antigenic patterns in comparison to that of VP2 on virions. An immunization experiment with four more horses confirmed these results. The vaccine described here would not only prevent the disease, but would drastically reduce the propagation of the virus by vectors.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-77-6-1211
1996-06-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/77/6/JV0770061211.html?itemId=/content/journal/jgv/10.1099/0022-1317-77-6-1211&mimeType=html&fmt=ahah

References

  1. Bremer C. W. 1976; A gel electrophoretic study of the protein and nucleic acid components of African horsesickness virus. Onderstepoort Journal of Veterinary Research 43:193–200
    [Google Scholar]
  2. Bremer C. W., Huismans H., Van Dijk A. A. 1990; Characterization and cloning of the African horsesickness virus genome. Journal of General Virology 71:793–799
    [Google Scholar]
  3. Burrage T. G., Trevejo R., Stone-Marschat M., Laegreid W. W. 1993; Neutralizing epitopes of African horsesickness virus serotype 4 are located on VP2. Virology 196:799–803
    [Google Scholar]
  4. Chuma T., le Blois H., Sánchez-Vizcaino J. M., Díaz-Laviada M., Roy P. 1992; Expression of the major core antigen VP7 of African horsesickness virus by a recombinant baculovirus and its use as a group-specific diagnostic reagent. Journal of General Virologv 73:925–931
    [Google Scholar]
  5. Dubourget P. H., Preaud J. M., Detraz N., Lacoste F., Fabry A. C., Erasmus B., Lombard M. 1992; Development, production and quality control of an industrial inactivated vaccine against AHSV type IV. In Second International Symposium on Bluetongue, African Horse Sickness and Related Orbiviruses pp. 874–886 Edited by Walton T. E., Osburn B. I. Boca Raton: CRC Press;
    [Google Scholar]
  6. Erasmus B. T. 1978; A new approach to polyvalent immunization against African horsesickness. In Proceeding of the Fourth International Conference on Equine Infectious Diseases pp. 401–103 Edited by Bryans T.J., Gerber H. Princeton: Veterinary Publications;
    [Google Scholar]
  7. French T. J., Marshall J. J. A., Roy P. 1990; Assembly of double-shelled, virus-like particles of bluetongue virus by the simultaneous expression of four structural proteins. Journal of Virology 64:5695–5700
    [Google Scholar]
  8. Holmes I. H. 1991; Family Reoviridae . In Classification and Nomenclature of VirusesFifth Report of the International Committee on Taxonomy of Viruses pp. Edited by 186–199 Francki R. I. B., Fauquet C. M., Knudson D. L., Brown F. Wein and New York: Springer-Verlag;
    [Google Scholar]
  9. House J. A., Lombard M., Dubourget P., House C., Mebus C. A. 1994; Further studies on the efficacy of an inactivated African horse sickness serotype 4 vaccine. Vaccine 12:142–144
    [Google Scholar]
  10. Inumaru S., Roy P. 1989; Development of bluetongue virus vaccine using a baculovirus expression vector. In Biotechnology for Livestock and Health pp. 347–357 New York: Plenum Press;
    [Google Scholar]
  11. Laviada M. D., Roy P., Sánchez-Vizcaíno J. M. 1992a; Adaptation and evaluation of an indirect ELISA and immunoblotting test for African horsesickness antibody detection. In Second International Symposium on Bluetongue, African Horse Sickness and Related Orbiviruses Edited by pp. 646–650 Walton T. E., Osburn B. I. Boca Raton: CRC Press;
    [Google Scholar]
  12. Laviada M. D., Babin M., Dominguez J., Sánchez-Vizcaíno J. M. 1992b; Detection of African horsesickness virus in infected spleens by a sandwich ELISA using two monoclonal antibodies specific for VP7. Journal of Virological Methods 38:229–242
    [Google Scholar]
  13. Laviada M. D., Roy P., Sánchez-Vizcaíno J. M., Casal J. I. 1995; The use of African horsesickness virus NS3 protein, expressed in bacteria, as a marker to differentiate infected from vaccinated horses. Virus Research 38:205–218
    [Google Scholar]
  14. Lubroth J. 1988; African horsesickness and the epizootic in Spain 1987. Equine Practice 10:26–33
    [Google Scholar]
  15. Martínez-Torrecuadrada J. L., Iwata H., Venteo A., Casal J. I., Roy P. 1994; Expression and characterization of the two outer capsid proteins of African horsesickness virus: the role of VP2 in virus neutralization. Virology 202:348–359
    [Google Scholar]
  16. Martínez-Torrecuadrada J. L., Casal J. I. 1995; Identification of a linear neutralization domain in the protein VP2 of African horsesickness virus. Virology 210:391–399
    [Google Scholar]
  17. Mellor P. S. 1990; The replication of bluetongue virus in Culicoides vector. Current Topics in Microbiology and Immunology 162:143–161
    [Google Scholar]
  18. Mellor P. 1993; African horsesickness transmission and epidemiology. Veterinary Research 24:199–212
    [Google Scholar]
  19. Mertens P. P. C., Burroughs J. N., Anderson J. 1987; Purification and properties of virus particles, infectious subviral particles and cores of bluetongue virus serotypes 1 and 4. Virology 157:375–386
    [Google Scholar]
  20. Oellermann R. A. 1970; Plaque formation by African horsesickness virus and characterization of its RNA. Onderstepoort Journal of Veterinary Research 37:137–144
    [Google Scholar]
  21. Oellermann R. A., Els H. J., Erasmus B. J. 1970; Characterization of African horsesickness virus. Archiv für die gesamte Virusforschung 29:163–174
    [Google Scholar]
  22. Osburn B. I. 1992; Immune responses to orbiviruses. In Second International Symposium on Bluetongue, African Horse Sickness and Related Orbiviruses pp. 511–524 Edited by Walton T. E., Osburn B. I. Boca Raton: CRC Press;
    [Google Scholar]
  23. Ranz A. I., Miguet J. G., Anaya C., Venteo A., Cortés E., Vela C., Sanz A. 1992; Diagnostic methods for African horsesickness virus using monoclonal antibodies to structural and nonstructural proteins. Veterinary Microbiology 33:143–153
    [Google Scholar]
  24. Rodríquez M., Hooghuis H., Castaño M. 1992; African horsesickness in Spain. Veterinary Microbiology 33:129–142
    [Google Scholar]
  25. Roy P., Urakawa T., Van Dijk A. A., Erasmus B. J. 1990; Recombinant virus vaccine for bluetongue disease in sheep. Journal of Virology 64:1998–2003
    [Google Scholar]
  26. Roy P., French T. J., Erasmus B. J. 1992; Protective efficacy of virus-like particles for bluetongue disease. Vaccine 10:28–32
    [Google Scholar]
  27. Roy P., Mertens P. P. C., Casal J. I. 1994a; African horsesickness virus structure. Comparative Immunology and Microbiology of Infectious Diseases 17:243–273
    [Google Scholar]
  28. Roy P., Bishop D. H. L., Leblois H., Erasmus B. J. 1994b; Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. Vaccine 12:805–811
    [Google Scholar]
  29. Yang Y.-Y., Johnson T. M., Mecham J. O., Tam J. P., Li J. K.-K. 1992; Epitopic mapping of linear and conformation-dependent antigenic determinants on gp5 of five US bluetongue viruses. Virology 188:530–536
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-77-6-1211
Loading
/content/journal/jgv/10.1099/0022-1317-77-6-1211
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error